Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-12-26 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2022年第二次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, qualifications, and voting results of a company's 2022 second extraordinary general meeting (临时股东大会). It details the legality and compliance of the meeting process, voting methods, and results. It does not contain financial statements, management discussion, or report content but rather a legal certification of the meeting's validity. The document length is 2579 characters, which is relatively short and focused on legal opinion rather than the meeting materials or results announcement. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the voting results and legality of the shareholder meeting proceedings.
2022-12-26 Chinese
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 second extraordinary general meeting of shareholders of Lingkang Pharmaceutical Group Co., Ltd. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal opinions on the meeting's legality. The content focuses on the voting results and procedural details of the shareholders' meeting rather than the meeting materials or presentations themselves. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is 3630 characters, which is sufficient to contain substantive voting results rather than just a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2022-12-26 Chinese
股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding a shareholder's plan to reduce their shareholding. It details the shareholder's current holdings, the planned reduction amount, methods, timing, and related commitments. The content focuses on shareholding changes by a shareholder and their intentions to sell shares, which aligns with a notification of transactions or changes in share ownership. It is not a financial report, earnings release, or management discussion. The document is not a report publication announcement or certification. It fits the category of Major Shareholding Notification, as it informs about a significant shareholder's planned reduction in shares.
2022-12-23 Chinese
关于以集中竞价交易方式回购公司股份比例达到总股本1%暨回购股份进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, including details on the number of shares repurchased, the percentage of total share capital repurchased, prices, and total amount spent. It references the company's board approval of the repurchase plan and compliance with regulatory requirements for disclosure. The document is short (1010 characters) and focuses on the update of share buyback activity rather than presenting financial statements or detailed financial analysis. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2022-12-20 Chinese
关于控股股东部分股份解除质押及重新办理质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the impact on the company's control and operations. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledge status, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share pledging and capital structure. The document length is short and focused on a specific capital-related event, not a full report or earnings release.
2022-12-19 Chinese
2022年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2022 second extraordinary general meeting of Lingkang Pharmaceutical Group Co., Ltd. It contains detailed meeting agenda, voting procedures, and multiple proposals for shareholder approval, including appointment of an audit firm, amendments to various governance rules, and other corporate governance matters. The content is typical of materials prepared for a shareholders' meeting to inform and solicit votes on specific resolutions. It is not a report itself but the meeting materials for an extraordinary general meeting (EGM). Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. The document length (8650 characters) and detailed agenda support this classification with high confidence.
2022-12-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.